An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma

Trial Profile

An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2016

At a glance

  • Drugs GDC 0084 (Primary)
  • Indications Glioblastoma; Glioma
  • Focus Adverse reactions; First in man
  • Sponsors Genentech
  • Most Recent Events

    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 12 Mar 2016 Results assessing pharmacokinetics presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 19 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top